Work

Phase 1b/2 study to assess the safety, tolerability, and clinical activity of BGB-290 in combination with temozolomide in patients with locally advanced or metastatic solid tumors

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx367.053

Authors: M. Johnson, B. Benson, R. Wei, R. Brachmann, M.D. Galsky

Institutions: Tennessee Oncology, Icahn School of Medicine at Mount Sinai

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2762764969

FWCI:

Cites:

Cited by:

Related to: 10